Seeking Alpha

Amgen (AMGN) says Phase 2 studies of its investigational antibody AMG 145, in combination with...

Amgen (AMGN) says Phase 2 studies of its investigational antibody AMG 145, in combination with statin therapy, resulted in a 56% reduction in low density lipoprotein cholesterol, the "bad" cholesterol, in patients with heterozygous familial hypercholesterolemia. The study was published in Circulation and presented at the American Heart Association Scientific Sessions 2012.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|